Risk of development discontinuation due to unconfirmed efficacy and safety
First written in FY2016. 11 of 12 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
29 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The Company has disclosed that there have been no material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2020RestatedAnnual report
「If R&D on the Company's products under development can no longer continue, this could have a material impact on its business plan.」
The Company continues to disclose the risk of development discontinuation due to failure to confirm efficacy or safety or changes in medical needs. - FY2019RestatedAnnual report
「If the utility and safety required of a pharmaceutical product cannot be confirmed, R&D will be discontinued. If R&D on the Company's products under development can no longer continue, this could have a material impact on its business plan.」
The Company continues to disclose the risk of development discontinuation due to failure to confirm efficacy or safety or changes in medical needs. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company has disclosed that there have been no material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2018RestatedAnnual report
「If the utility and safety required of a pharmaceutical product cannot be confirmed, R&D will be discontinued.」
The Company continues to disclose the risk of development discontinuation due to failure to confirm efficacy or safety or changes in medical needs. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company has disclosed that there have been no new developments or material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company has disclosed that there have been no material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2017RestatedAnnual report
「If the expected effects cannot be confirmed in nonclinical or clinical trials, unexpected adverse effects occur, or changes in standard treatment methods or other practices in the medical field during the R&D period make it difficult to establish the utility of a product under development in meeting medical needs, among other circumstances, R&D will be discontinued if the utility and safety required of a pharmaceutical product cannot be confirmed.」
The Company continues to disclose the risk of development discontinuation due to failure to confirm efficacy or safety or changes in medical needs. - FY2017-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company has disclosed that there have been no material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2017-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company has disclosed that there have been no new developments or material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2017-Q1RestatedAnnual report
「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The Company has disclosed that there have been no material changes regarding the risk of development discontinuation if the utility and safety of a pharmaceutical product cannot be confirmed. - FY2016First statedAnnual report
「If the expected effects cannot be confirmed in nonclinical or clinical trials, unexpected adverse effects occur, or changes in standard treatment methods or other practices in the medical field during the R&D period make it difficult to establish the utility of a product under development in meeting medical needs, among other circumstances, R&D will be discontinued if the utility and safety required of a pharmaceutical product cannot be confirmed.」
The Company discloses the possibility that R&D may be discontinued due to failure to confirm efficacy or safety or changes in medical needs.